Amring Pharmaceuticals changes name to Nordic Pharma
Click Here to Manage Email Alerts
Amring Pharmaceuticals has changed its name to Nordic Pharma following its recent acquisition by Nordic Group, part of a strategy to expand the parent company’s branded and generic eye care products in the U.S. and abroad.
“The strategic acquisition and merger of the U.S. business unit is a cornerstone of Nordic Pharma’s global expansion,” CEO Charlotte Phelps said in a company press release. “With a range of ophthalmology products currently in phase 2 development, combining this with our existing assets and leveraging the expertise of our U.S. leadership in ophthalmics is imperative for driving the success of these programs.”
This news follows Nordic Pharma’s recent acquisition of Visant Medical, which included the FDA-cleared Lacrifill canalicular gel, a hyaluronic acid derivative for dry eye disease designed to temporarily block tear drainage by occlusion of the canalicular system. The company will launch Lacrifill in the U.S. in early 2024, followed by a global rollout.
“I’m excited to be leading Nordic Pharma U.S. at this dynamic stage of the company as we continue focusing on providing quality generics to our customers and their patients in the U.S. while building out an innovative proprietary ophthalmic business,” Philip Gioia, president of Nordic Pharma U.S., said in the release. “The timing could not be better as new ophthalmic innovations are becoming near-term ready for commercialization, and I believe Nordic Pharma can capitalize and compete effectively as a newer specialty ophthalmic player in the U.S. and globally.”
Read more about
Click Here to Manage Email Alerts